EndophthalmitisNCT07888205
Vitrectomy Combined With Povidone-Iodine Vitreous Irrigation for Infectious Endophthalmitis
A study testing Povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodine and BSS intravitreal irrigation solution in people with Endophthalmitis and Infectious Endophthalmitis, run by Beijing Tongren Hospital.
Trial summary
Infectious endophthalmitis is a severe infection inside the eye that can rapidly cause permanent vision loss or loss of the eye. Standard treatment usually includes vitrectomy, a surgical procedure that removes infected vitreous gel, together with antibiotics. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Endophthalmitis, Infectious Endophthalmitis
- What is being tested?
- Povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodine and BSS intravitreal irrigation solution
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 38 participants
- Where
- No sites listed yet
- Study dates
- 30 Oct 2026to 30 Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The clinical diagnosis is infectious endophthalmitis, including postoperative endophthalmitis, post-traumatic endophthalmitis, endogenous endophthalmitis, etc.
- The tested eyes presented with clinical manifestations of endophthalmitis such as red eyes, eye pain, decreased vision, anterior chamber inflammation, and vitreous opacity.
- The researchers determined that the condition required vitrectomy and standard anti-infection treatment.
- The subject himself/herself or his/her legal representative signs the informed consent form.
- Be able to complete the follow-up as required by the plan.
Who cannot join
- People who are allergic to povidone-iodine or its components.
- Those with severe underlying eye diseases that significantly affect the determination of the primary outcome, such as advanced macular degeneration, end-stage glaucoma, and severe retinal degeneration, etc.
- Pregnant or lactating women.
- Those with severe immunosuppression or extremely poor overall condition who cannot tolerate surgery.
- Those with confirmed retinal detachment (RD) at the first diagnosis
- Those who have recently participated in other interventional clinical studies and may affect the outcomes of this study.
- Other circumstances that the researchers consider unsuitable for enrollment.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Randomized Controlled Trial of Vitrectomy Combined With Povidone-Iodine Vitreous Irrigation for Infectious Endophthalmitis
Infectious endophthalmitis is a severe infection inside the eye that can rapidly cause permanent vision loss or loss of the eye. Standard treatment usually includes vitrectomy, a surgical procedure that removes infected vitreous gel, together with antibiotics. However, infection may remain difficult to control, particularly when the causative microorganism is unknown or resistant to commonly used antibiotics.
Povidone-iodine is a broad-spectrum antiseptic that acts rapidly against many types of bacteria, fungi, and other microorganisms. It is routinely used to disinfect the surface of the eye before surgery, but its use inside the eye for treating established infection is still investigational.
Read more
The purpose of this study is to determine whether brief irrigation of the vitreous cavity with a low concentration of povidone-iodine can improve infection control when added to standard vitrectomy and antimicrobial treatment. The main question is whether irrigation with povidone-iodine containing 0.0025% available iodine increases the proportion of patients whose infection is controlled by 14 days without silicone oil tamponade, compared with irrigation using standard balanced salt solution alone.
This is a single-center, prospective, randomized, parallel-group clinical study involving approximately 38 patients with infectious endophthalmitis. Participants will be assigned in a 1:1 ratio according to the severity of inflammation at enrollment. After vitrectomy has been completed, patients in the study group will receive vitreous cavity irrigation with povidone-iodine containing 0.0025% available iodine for 2 minutes. The solution will then be removed from the eye. Patients in the control group will undergo the same surgical procedure using balanced salt solution without povidone-iodine. Both groups will otherwise receive appropriate standard antimicrobial treatment and clinical care.
The study hypothesis is that brief exposure to low-concentration povidone-iodine will rapidly reduce the number of microorganisms remaining in the eye and improve infection control without causing clinically significant damage to the retina, cornea, or other eye structures.
In addition to the primary outcome of infection control at Day 14 without silicone oil tamponade, the study will evaluate several secondary outcomes，including changes in best-corrected visual acuity, the need for additional eye surgery, and vision-related quality of life. Safety outcomes will include changes in retinal function measured by electroretinography, retinal structure assessed by optical coherence tomography, corneal endothelial cell density, intraocular pressure, and the occurrence and severity of adverse events throughout follow-up.
- Conditions
- Endophthalmitis, Infectious Endophthalmitis
- Being tested
- Povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodine, BSS intravitreal irrigation solution
- Keywords
- Infectious Endophthalmitis, Povidone-Iodine, Vitrectomy, Intravitreal Irrigation, Randomized Controlled Trial
- Medical subject headings
- Endophthalmitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodineProcedure or surgery
After the vitrectomy was completed, povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodine was used for 2 minutes.The solution will then be removed from the eye.
BSS intravitreal irrigation solutionProcedure or surgery
After vitrectomy, balanced salt solution (BSS) without povidone-iodine was used for intravitreal irrigation.
| Study group | Role | What they receive |
|---|---|---|
| PI Irrigation Group | Experimental | Standard Pars Plana Vitrectomy combined with intravitreal irrigation using povidone-iodine containing 0.0025% available iodine solution for 2 minutes after vitrectomy completion. Standard perioperative anti-infective treatment applied. Silicone oil tamponade is strictly on demand. Receives: Procedure: Povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodine |
| Standard BSS Group | Active comparator | Standard Pars Plana Vitrectomy with intraoperative Balanced Salt Solution (BSS) irrigation (PI-free). Standard perioperative anti-infective treatment applied identically to the experimental arm. Silicone oil tamponade is strictly on demand. Receives: Procedure: BSS intravitreal irrigation solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Infection control rate without silicone oil tamponade
The infection control rate of the patient without silicone oil tamponade 14 days after the operation
Measured: Day 14
Secondary outcomes (1)
Best-Corrected Visual Acuity (BCVA) Change
Change in LogMAR BCVA from baseline to post-op follow-up points.
Measured: Baseline, Day 7, Month 1, Month 3, and Month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study start30 Oct 2026 (estimated)
- Primary completion30 Mar 2028 (estimated)
- Study completion30 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (24)Papers the sponsor has linked to this study.
- Other trials for EndophthalmitisStudies of the same condition, open and under way.
- More trials run by Beijing Tongren HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 38 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tongren Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07888205
- Sponsor's protocol ID
- TREC2026-KY198
- Status last verified
- Sep 2026
- First submitted
- 14 Oct 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Lee SM, Lee S, Chae WJ, Park HS. Comparison of Clinical Outcomes of Intravitreal 0.625% Povidone-Iodine versus Antibiotic Injection for Postoperative Endophthalmitis. Korean J Ophthalmol. 2026 Jun;40(3):301-307. doi: 10.3341/kjo.2025.0147. Epub 2026 Mar 4.
PubMed 41776375Mi X, Malbin B, Lin X. Intraocular Povidone Iodine During Pars Plana Vitrectomy for Severe and Atypical Endophthalmitis. Ophthalmic Surg Lasers Imaging Retina. 2021 Sep;52(9):485-490. doi: 10.3928/23258160-20210820-01. Epub 2021 Sep 1.
PubMed 34505805Kitagawa Y, Shimada H, Nakashizuka H, Hattori T, Yamazaki Y. Intraocular lens implantation and vitrectomy using 0.025% povidone-iodine in irrigation solution for bleb-related endophthalmitis. Int J Ophthalmol. 2020 Sep 18;13(9):1499-1502. doi: 10.18240/ijo.2020.09.24. eCollection 2020. No abstract available.
PubMed 32953592Nakashizuka H, Shimada H, Hattori T, Tanaka K, Kitagawa Y, Shinoda K. Intravitreal Injection of 1.25% Povidone Iodine Followed by Vitrectomy Using 0.025% Povidone Iodine Irrigation for Treating Endophthalmitis. Transl Vis Sci Technol. 2019 Feb 13;8(1):21. doi: 10.1167/tvst.8.1.21. eCollection 2019 Jan.
PubMed 30783556Nakashizuka H, Shimada H, Hattori T, Noguchi T, Kokubo N, Yuzawa M. Vitrectomy using 0.025% povidone-iodine in balanced salt solution plus for the treatment of postoperative endophthalmitis. Retina. 2015 Jun;35(6):1087-94. doi: 10.1097/IAE.0000000000000634.
PubMed 25946690Machida Y, Nakashizuka H, Onoe H, Kitagawa Y, Nakagawa N, Miyata K, Yamakawa M, Wakatsuki Y, Tanaka K, Mori R, Shimada H. Intravitreal Povidone-Iodine Injection and Low-Dose Antibiotic Irrigation for Infectious Endophthalmitis: A Retrospective Case Series. Pharmaceutics. 2025 Jul 31;17(8):995. doi: 10.3390/pharmaceutics17080995.
PubMed 40871017Kim KH, Cao J, Yoo JW, Yoon IS, Jung JW, Lee JE, Byon IS. Intraocular Pharmacokinetics of Povidone-Iodine and Its Effects on Experimental Staphylococcus epidermidis Endophthalmitis. Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6694-700. doi: 10.1167/iovs.15-17739.
PubMed 26469754Shimada H, Kato K, Ishida K, Yamaguchi T, Shinoda K. Evaluation of Retinal Function and Pathology After Intravitreal Injection of Povidone-Iodine and Polyvinyl Alcohol-Iodine in Rabbits. Transl Vis Sci Technol. 2020 Apr 15;9(5):5. doi: 10.1167/tvst.9.5.5. eCollection 2020 Apr.
PubMed 32821477Soleimani M, Haydar AA, Cheraqpour K, Zeidabadinejad H, Esfandiari A, Eshaghhosseiny N, Shahmohammadi A, Banz S, Djalilian AR. In praise of povidone-iodine application in ophthalmology. Surv Ophthalmol. 2024 Mar-Apr;69(2):211-223. doi: 10.1016/j.survophthal.2023.11.002. Epub 2023 Nov 8.
PubMed 37944600Tanaka H, Nakashizuka H, Mizuno Y, Hattori T. Endogenous Endophthalmitis successfully treated with Intravitreal Povidone-iodine injection: a case report. BMC Ophthalmol. 2020 Jun 5;20(1):217. doi: 10.1186/s12886-020-01487-w.
PubMed 32503467Meehan JP. Dilute Povidone-Iodine Irrigation: The Science of Molecular Iodine (I2) Kinetics and Its Antimicrobial Activity. J Am Acad Orthop Surg. 2025 Jan 15;33(2):65-73. doi: 10.5435/JAAOS-D-24-00471. Epub 2024 Oct 8.
PubMed 39729104Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, Pyon JK, Wa CTC, Villa MA. Povidone iodine in wound healing: A review of current concepts and practices. Int J Surg. 2017 Aug;44:260-268. doi: 10.1016/j.ijsu.2017.06.073. Epub 2017 Jun 23.
PubMed 28648795Das T, Belenje A, Joseph J, Pandey S, Pandya D, Pandya R, Behera UC, Dave VP. Acute fungal post-cataract endophthalmitis in the endophthalmitis management study: EMS report 7. BMJ Open Ophthalmol. 2025 Aug 19;10(1):e002190. doi: 10.1136/bmjophth-2025-002190.
PubMed 40835237Das T, Pandey S, Joseph J, Sheth J, Belenje A, Behera UC, Kapoor A, Pandya R, Dave VP. Antibiotic susceptibility in Endophthalmitis Management Study and intravitreal antibiotic practice trend in India-EMS Report #5. Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2163-2169. doi: 10.1007/s00417-024-06391-3. Epub 2024 Feb 6.
PubMed 38319381Dave VP, Belenje A, Dogra A, Das T; EMS working group. Application and validation of a novel inflammatory score in the clinical grading of infectious endophthalmitis: The endophthalmitis management study - Report 2. Indian J Ophthalmol. 2023 Feb;71(2):396-400. doi: 10.4103/ijo.IJO_1274_22.
PubMed 36727325
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial of Vitrectomy Combined With Povidone-Iodine Vitreous Irrigation for Infectious Endophthalmitis
- ClinicalTrials.gov ID
- NCT07888205
- Acronym / sponsor ID
- TREC2026-KY198
- Conditions
- Endophthalmitis, Infectious Endophthalmitis
- Keywords
- Infectious Endophthalmitis, Povidone-Iodine, Vitrectomy, Intravitreal Irrigation, Randomized Controlled Trial
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 38 participants (estimated)
- Lead sponsor
- Beijing Tongren HospitalUniversity, hospital or other
- Study start
- 30 Oct 2026 (estimated)
- Primary completion
- 30 Mar 2028 (estimated)
- Study completion
- 30 Sep 2028 (estimated)
- First posted
- 22 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Infectious endophthalmitis is a severe infection inside the eye that can rapidly cause permanent vision loss or loss of the eye. Standard treatment usually includes vitrectomy, a surgical procedure that removes infected vitreous gel, together with antibiotics. However, infection may remain difficult to control, particularly when the causative microorganism is unknown or resistant to commonly used antibiotics.
Povidone-iodine is a broad-spectrum antiseptic that acts rapidly against many types of bacteria, fungi, and other microorganisms. It is routinely used to disinfect the surface of the eye before surgery, but its use inside the eye for treating established infection is still investigational.
The purpose of this study is to determine whether brief irrigation of the vitreous cavity with a low concentration of povidone-iodine can improve infection control when added to standard vitrectomy and antimicrobial treatment. The main question is whether irrigation with povidone-iodine containing 0.0025% available iodine increases the proportion of patients whose infection is controlled by 14 days without silicone oil tamponade, compared with irrigation using standard balanced salt solution alone.
This is a single-center, prospective, randomized, parallel-group clinical study involving approximately 38 patients with infectious endophthalmitis. Participants will be assigned in a 1:1 ratio according to the severity of inflammation at enrollment. After vitrectomy has been completed, patients in the study group will receive vitreous cavity irrigation with povidone-iodine containing 0.0025% available iodine for 2 minutes. The solution will then be removed from the eye. Patients in the control group will undergo the same surgical procedure using balanced salt solution without povidone-iodine. Both groups will otherwise receive appropriate standard antimicrobial treatment and clinical care.
The study hypothesis is that brief exposure to low-concentration povidone-iodine will rapidly reduce the number of microorganisms remaining in the eye and improve infection control without causing clinically significant damage to the retina, cornea, or other eye structures.
In addition to the primary outcome of infection control at Day 14 without silicone oil tamponade, the study will evaluate several secondary outcomes，including changes in best-corrected visual acuity, the need for additional eye surgery, and vision-related quality of life. Safety outcomes will include changes in retinal function measured by electroretinography, retinal structure assessed by optical coherence tomography, corneal endothelial cell density, intraocular pressure, and the occurrence and severity of adverse events throughout follow-up.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PI Irrigation Group | Experimental | Procedure: Povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodineStandard Pars Plana Vitrectomy combined with intravitreal irrigation using povidone-iodine containing 0.0025% available iodine solution for 2 minutes after vitrectomy completion. Standard perioperative anti-infective treatment applied. Silicone oil tamponade is strictly on demand. |
| Standard BSS Group | Active comparator | Procedure: BSS intravitreal irrigation solutionStandard Pars Plana Vitrectomy with intraoperative Balanced Salt Solution (BSS) irrigation (PI-free). Standard perioperative anti-infective treatment applied identically to the experimental arm. Silicone oil tamponade is strictly on demand. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- The clinical diagnosis is infectious endophthalmitis, including postoperative endophthalmitis, post-traumatic endophthalmitis, endogenous endophthalmitis, etc.
- The tested eyes presented with clinical manifestations of endophthalmitis such as red eyes, eye pain, decreased vision, anterior chamber inflammation, and vitreous opacity.
- The researchers determined that the condition required vitrectomy and standard anti-infection treatment.
- The subject himself/herself or his/her legal representative signs the informed consent form.
- Be able to complete the follow-up as required by the plan.
Key exclusion criteria (7 listed)
- People who are allergic to povidone-iodine or its components.
- Those with severe underlying eye diseases that significantly affect the determination of the primary outcome, such as advanced macular degeneration, end-stage glaucoma, and severe retinal degeneration, etc.
- Pregnant or lactating women.
- Those with severe immunosuppression or extremely poor overall condition who cannot tolerate surgery.
- Those with confirmed retinal detachment (RD) at the first diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodineAfter the vitrectomy was completed, povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodine was used for 2 minutes.The solution will then be removed from the eye. | Procedure or surgery | PI Irrigation Group |
| BSS intravitreal irrigation solutionAfter vitrectomy, balanced salt solution (BSS) without povidone-iodine was used for intravitreal irrigation. | Procedure or surgery | Standard BSS Group |
Primary outcome
Infection control rate without silicone oil tamponade
Time frame: Day 14
The infection control rate of the patient without silicone oil tamponade 14 days after the operation
1 secondary outcome
Best-Corrected Visual Acuity (BCVA) Change
Time frame: Baseline, Day 7, Month 1, Month 3, and Month 6
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Background: PubMed 41776375Lee SM, Lee S, Chae WJ, Park HS. Comparison of Clinical Outcomes of Intravitreal 0.625% Povidone-Iodine versus Antibiotic Injection for Postoperative Endophthalmitis. Korean J Ophthalmol. 2026 Jun;40(3):301-307. doi: 10.3341/kjo.2025.0147. Epub 2026 Mar 4.
- Background: PubMed 34505805Mi X, Malbin B, Lin X. Intraocular Povidone Iodine During Pars Plana Vitrectomy for Severe and Atypical Endophthalmitis. Ophthalmic Surg Lasers Imaging Retina. 2021 Sep;52(9):485-490. doi: 10.3928/23258160-20210820-01. Epub 2021 Sep 1.
- Background: PubMed 32953592Kitagawa Y, Shimada H, Nakashizuka H, Hattori T, Yamazaki Y. Intraocular lens implantation and vitrectomy using 0.025% povidone-iodine in irrigation solution for bleb-related endophthalmitis. Int J Ophthalmol. 2020 Sep 18;13(9):1499-1502. doi: 10.18240/ijo.2020.09.24. eCollection 2020. No abstract available.
- Background: PubMed 30783556Nakashizuka H, Shimada H, Hattori T, Tanaka K, Kitagawa Y, Shinoda K. Intravitreal Injection of 1.25% Povidone Iodine Followed by Vitrectomy Using 0.025% Povidone Iodine Irrigation for Treating Endophthalmitis. Transl Vis Sci Technol. 2019 Feb 13;8(1):21. doi: 10.1167/tvst.8.1.21. eCollection 2019 Jan.
- Background: PubMed 25946690Nakashizuka H, Shimada H, Hattori T, Noguchi T, Kokubo N, Yuzawa M. Vitrectomy using 0.025% povidone-iodine in balanced salt solution plus for the treatment of postoperative endophthalmitis. Retina. 2015 Jun;35(6):1087-94. doi: 10.1097/IAE.0000000000000634.
- Background: PubMed 40871017Machida Y, Nakashizuka H, Onoe H, Kitagawa Y, Nakagawa N, Miyata K, Yamakawa M, Wakatsuki Y, Tanaka K, Mori R, Shimada H. Intravitreal Povidone-Iodine Injection and Low-Dose Antibiotic Irrigation for Infectious Endophthalmitis: A Retrospective Case Series. Pharmaceutics. 2025 Jul 31;17(8):995. doi: 10.3390/pharmaceutics17080995.
- Background: PubMed 26469754Kim KH, Cao J, Yoo JW, Yoon IS, Jung JW, Lee JE, Byon IS. Intraocular Pharmacokinetics of Povidone-Iodine and Its Effects on Experimental Staphylococcus epidermidis Endophthalmitis. Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6694-700. doi: 10.1167/iovs.15-17739.
- Background: PubMed 32821477Shimada H, Kato K, Ishida K, Yamaguchi T, Shinoda K. Evaluation of Retinal Function and Pathology After Intravitreal Injection of Povidone-Iodine and Polyvinyl Alcohol-Iodine in Rabbits. Transl Vis Sci Technol. 2020 Apr 15;9(5):5. doi: 10.1167/tvst.9.5.5. eCollection 2020 Apr.
- Background: PubMed 37944600Soleimani M, Haydar AA, Cheraqpour K, Zeidabadinejad H, Esfandiari A, Eshaghhosseiny N, Shahmohammadi A, Banz S, Djalilian AR. In praise of povidone-iodine application in ophthalmology. Surv Ophthalmol. 2024 Mar-Apr;69(2):211-223. doi: 10.1016/j.survophthal.2023.11.002. Epub 2023 Nov 8.
- Background: PubMed 32503467Tanaka H, Nakashizuka H, Mizuno Y, Hattori T. Endogenous Endophthalmitis successfully treated with Intravitreal Povidone-iodine injection: a case report. BMC Ophthalmol. 2020 Jun 5;20(1):217. doi: 10.1186/s12886-020-01487-w.
- Background: PubMed 39729104Meehan JP. Dilute Povidone-Iodine Irrigation: The Science of Molecular Iodine (I2) Kinetics and Its Antimicrobial Activity. J Am Acad Orthop Surg. 2025 Jan 15;33(2):65-73. doi: 10.5435/JAAOS-D-24-00471. Epub 2024 Oct 8.
- Background: PubMed 28648795Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, Pyon JK, Wa CTC, Villa MA. Povidone iodine in wound healing: A review of current concepts and practices. Int J Surg. 2017 Aug;44:260-268. doi: 10.1016/j.ijsu.2017.06.073. Epub 2017 Jun 23.
- Individual participant dataSharing planned: No
Related trials for Endophthalmitis
RecruitingObservational study
Nanopore Sequencing in Ophthalmology
Endophthalmitis
Not yet recruiting
Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery
Cataract, Postoperative Endophthalmitis
RecruitingPhase 1
A Study of Ear Nerve Stimulation to Treat Eye Inflammation
Ocular Inflammation, Crystalline Lens; Chalcosis
Not yet recruitingPhase 2/3
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Endophthalmitis
Active, not recruiting
Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles
Uveitis Posterior Non-Infectious, Inflammation Eye
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Povidone-iodine intravitreal irrigation with povidone-iodine containing 0.0025% available iodine and BSS intravitreal irrigation solution in people with Endophthalmitis and Infectious Endophthalmitis, run by Beijing Tongren Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yanyun Chen, M. D. (010-58268430, yanyun_chen@ccmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Infection control rate without silicone oil tamponade (time frame: Day 14). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07888205, which also lists 24 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.